CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Clinical trials for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) explained in plain language.
Never miss a new study
Get alerted when new CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) trials appear
Sign up with your email to follow new studies for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-world check: does ilaris work safely for rare fever diseases?
Disease control Recruiting nowThis study watches children and adults who are already taking or about to start Ilaris for hereditary periodic fever syndromes or systemic juvenile idiopathic arthritis. Researchers will track side effects and how well the drug controls symptoms over 16 weeks. No new medicine is …
Matched conditions: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New CAPS pill enters first human tests
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called JTE-162 in 5 adults with CAPS, a rare condition that causes fever, rash, and joint pain. Participants take one tablet daily for 2 weeks. Researchers will check if the drug safely reduces inflammation and improves sympt…
Matched conditions: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Phase: PHASE1 • Sponsor: Akros Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC